Dosage & Administration Drug label Prior authorization Financial assistance

Kanuma

(sebelipase alfa)

10 ML sebelipase alfa 2 MG/ML Injection [Kanuma]

NO BLACK BOX WARNING

Dosage & administration

Infants with Rapidly Progressive LAL Deficiency Presenting within the First 6 Months of Life:

* The recommended starting dosage is 1 mg/kg as an intravenous infusion once weekly.
* For patients with a suboptimal clinical response, increase the dosage to 3 mg/kg once weekly.
* For patients with continued suboptimal clinical response, further increase the dosage to 5 mg/kg once weekly.

Pediatric and Adult Patients with LAL Deficiency:

* The recommended dosage is 1 mg/kg as an intravenous infusion once every other week.
* For patients with a suboptimal clinical response, increase the dosage to 3 mg/kg once every other week.

See Full Prescribing Information for complete Dosage and Administration Information.

Administration Instructions

* Infuse over at least 2 hours.
* Consider further prolonging the infusion time for patients receiving dosages greater than 1 mg/kg or for those who have experienced a hypersensitivity reaction.
* Consider a 1-hour infusion for the 1 mg/kg dose in patients who tolerate the infusion.

Kanuma prescribing information

Have more Kanuma questions?

Submit MSL Request

Learn More

Need to report a Kanuma issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Kanuma Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

NOT PROVIDED BY BRANDCoverage Authorization Appeals

Learn More

Benefits investigation

Kanuma OneSource Enrollment Form

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Kanuma Financial assistance options

Co-pay savings program

commercial only

Kanuma OneSource Enrollment Form

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Kanuma Patient education

Getting started on Kanuma

NOT PROVIDED BY BRANDInstructions For Use - Lysosomal Acid Lipase Deficiency (LAL-D)

Patient toolkit

NOT PROVIDED BY BRANDNot Provided By Brand

Learn More

Kanuma FAQs

FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:

Please note:

Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.

Kanuma

Dosage & administration

Most viewed Kanuma resources

drug label

Kanuma prescribing information

Have more Kanuma questions?

Need to report a Kanuma issue?

prior authorization

Kanuma Prior authorization resources

Benefits investigation

Reimbursement help (FRM)

financial assistance

Kanuma Financial assistance options

Co-pay savings program

Overview

Patient benefit

Patient eligibility

How to sign up

Bridge program

Overview

Patient benefit

Patient eligibility

How to sign up

Foundation programs

Overview

Patient benefit

Patient eligibility

How to sign up

patient education

Kanuma Patient education

Getting started on Kanuma

Patient toolkit

people also ask

Kanuma FAQs

Can't find what you're looking for?